Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease
- 1 July 2008
- journal article
- review article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 14 (Suppl 2) , S116-S118
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's diseaseExperimental Neurology, 2007
- Rat model of Parkinson's disease: Chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+)Experimental Neurology, 2006
- Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and α-synucleinProceedings of the National Academy of Sciences, 2005
- Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Experimental Neurology, 2004
- Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatmentNeuroscience, 2001
- Chronic systemic pesticide exposure reproduces features of Parkinson's diseaseNature Neuroscience, 2000
- Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell LinesExperimental Neurology, 2000
- ULTRASTRUCTURAL-CHANGES OF THE SUBSTANTIA NIGRA, VENTRAL TEGMENTAL AREA AND STRIATUM IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)-TREATED MICE1990
- Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkeyActa Neuropathologica, 1988